TY - STD TI - Cancer Survival Statistics, 2008–2014, Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, Bethesda, MD [Internet]; 2008–2014. http://www.seer.cancer.gov. UR - http://www.seer.cancer.gov ID - ref1 ER - TY - JOUR AU - Leibovich, B. C. AU - Lohse, C. M. AU - Crispen, P. L. AU - Boorjian, S. A. AU - Thompson, R. H. AU - Blute, M. L. PY - 2010 DA - 2010// TI - Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma JO - J Urol VL - 183 UR - https://doi.org/10.1016/j.juro.2009.12.035 DO - 10.1016/j.juro.2009.12.035 ID - Leibovich2010 ER - TY - JOUR AU - Gnarra, J. R. AU - Tory, K. AU - Weng, Y. AU - Schmidt, L. AU - Wei, M. H. AU - Li, H. PY - 2019 DA - 2019// TI - Mutations of the VHL tumour suppressor gene in renal carcinoma JO - Nat Genet VL - 7 UR - https://doi.org/10.1038/ng0594-85 DO - 10.1038/ng0594-85 ID - Gnarra2019 ER - TY - JOUR AU - McDermott, D. F. AU - Regan, M. M. AU - Clark, J. I. AU - Flaherty, L. E. AU - Weiss, G. R. AU - Logan, T. F. PY - 2005 DA - 2005// TI - Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.03.206 DO - 10.1200/JCO.2005.03.206 ID - McDermott2005 ER - TY - JOUR AU - Itsumi, M. AU - Tatsugami, K. PY - 2010 DA - 2010// TI - Immunotherapy for renal cell carcinoma JO - Clin Dev Immunol UR - https://doi.org/10.1155/2010/284581 DO - 10.1155/2010/284581 ID - Itsumi2010 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Tomczak, P. AU - Michaelson, M. D. AU - Bukowski, R. M. AU - Rixe, O. PY - 2009 DA - 2009// TI - Sunitinib versus interferon alfa in metastatic renal-cell carcinoma JO - N Engl J Med UR - https://doi.org/10.1056/NEJMoa065044 DO - 10.1056/NEJMoa065044 ID - Motzer2009 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. AU - Aren Frontera, O. AU - Melichar, B. AU - Choueiri, T. K. PY - 2018 DA - 2018// TI - Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - JOUR AU - Rini, B. I. AU - Plimack, E. R. AU - Stus, V. AU - Gafanov, R. AU - Hawkins, R. AU - Nosov, D. PY - 2019 DA - 2019// TI - Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1816714 DO - 10.1056/NEJMoa1816714 ID - Rini2019 ER - TY - JOUR AU - Pignon, J. -. C. AU - Jegede, O. AU - Mahoney, K. M. AU - Moreira, R. B. AU - Novak, J. AU - Conen, H. PY - 2017 DA - 2017// TI - Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC) JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.6_suppl.477 DO - 10.1200/JCO.2017.35.6_suppl.477 ID - Pignon2017 ER - TY - JOUR AU - Zhu, J. AU - Armstrong, A. J. AU - Friedlander, T. W. AU - Kim, W. AU - Pal, S. K. AU - George, D. J. PY - 2018 DA - 2018// TI - Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond JO - J ImmunoTher Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0314-1 DO - 10.1186/s40425-018-0314-1 ID - Zhu2018 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Maia, M. C. AU - Almeida, L. AU - Bergerot, P. G. AU - Dizman, N. AU - Pal, S. K. PY - 2018 DA - 2018// TI - Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC) JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.6_suppl.662 DO - 10.1200/JCO.2018.36.6_suppl.662 ID - Maia2018 ER - TY - JOUR AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Tumor mutational burden and response rate to PD-1 inhibition JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1713444 DO - 10.1056/NEJMc1713444 ID - Yarchoan2017 ER - TY - JOUR AU - Harlin, H. AU - Meng, Y. AU - Peterson, A. C. AU - Zha, Y. AU - Tretiakova, M. AU - Slingluff, C. PY - 2009 DA - 2009// TI - Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2281 DO - 10.1158/0008-5472.CAN-08-2281 ID - Harlin2009 ER - TY - JOUR AU - Ribas, A. AU - Robert, C. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Joshua, A. M. AU - Hwu, W. -. J. PY - 2015 DA - 2015// TI - Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/jco.2015.33.15_suppl.3001 DO - 10.1200/jco.2015.33.15_suppl.3001 ID - Ribas2015 ER - TY - JOUR AU - Ayers, M. AU - Lunceford, J. AU - Nebozhyn, M. AU - Murphy, E. AU - Loboda, A. AU - Kaufman, D. R. PY - 2017 DA - 2017// TI - IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade JO - J Clin Invest. VL - 127 UR - https://doi.org/10.1172/JCI91190 DO - 10.1172/JCI91190 ID - Ayers2017 ER - TY - JOUR AU - Brauer, M. J. AU - Zhuang, G. AU - Schmidt, M. AU - Yao, J. AU - Wu, X. AU - Kaminker, J. S. PY - 2013 DA - 2013// TI - Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3635 DO - 10.1158/1078-0432.CCR-12-3635 ID - Brauer2013 ER - TY - JOUR AU - McDermott, D. F. AU - Huseni, M. A. AU - Atkins, M. B. AU - Motzer, R. J. AU - Rini, B. I. AU - Escudier, B. PY - 2018 DA - 2018// TI - Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0053-3 DO - 10.1038/s41591-018-0053-3 ID - McDermott2018 ER - TY - JOUR AU - Oken, M. M. AU - Creech, R. H. AU - Tormey, D. C. AU - Horton, J. AU - Davis, T. E. AU - McFadden, E. T. PY - 1982 DA - 1982// TI - Toxicity and response criteria of the Eastern Cooperative Oncology Group JO - Am J Clin Oncol VL - 5 UR - https://doi.org/10.1097/00000421-198212000-00014 DO - 10.1097/00000421-198212000-00014 ID - Oken1982 ER - TY - JOUR AU - Buccheri, G. AU - Ferrigno, D. AU - Tamburini, M. PY - 1996 DA - 1996// TI - Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution JO - Eur J Cancer VL - 32a UR - https://doi.org/10.1016/0959-8049(95)00664-8 DO - 10.1016/0959-8049(95)00664-8 ID - Buccheri1996 ER - TY - JOUR AU - Heng, D. Y. AU - Xie, W. AU - Regan, M. M. AU - Warren, M. A. AU - Golshayan, A. R. AU - Sahi, C. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.4809 DO - 10.1200/JCO.2008.21.4809 ID - Heng2009 ER - TY - JOUR AU - Ko, J. J. AU - Xie, W. AU - Kroeger, N. AU - Lee, J. L. AU - Rini, B. I. AU - Knox, J. J. PY - 2015 DA - 2015// TI - The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71222-7 DO - 10.1016/S1470-2045(14)71222-7 ID - Ko2015 ER - TY - JOUR AU - Shah, S. AU - Wood, K. AU - Labadie, B. AU - Won, B. AU - Brisson, R. AU - Karrison, T. PY - 2018 DA - 2018// TI - Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer JO - Oncotarget. VL - 9 ID - Shah2018 ER - TY - JOUR AU - McQuade, J. L. AU - Daniel, C. R. AU - Hess, K. R. AU - Mak, C. AU - Wang, D. Y. AU - Rai, R. R. PY - 2018 DA - 2018// TI - Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30078-0 DO - 10.1016/S1470-2045(18)30078-0 ID - McQuade2018 ER - TY - JOUR AU - Richtig, G. AU - Hoeller, C. AU - Wolf, M. AU - Wolf, I. AU - Rainer, B. M. AU - Schulter, G. PY - 2018 DA - 2018// TI - Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study JO - PLoS ONE VL - 13 UR - https://doi.org/10.1371/journal.pone.0204729 DO - 10.1371/journal.pone.0204729 ID - Richtig2018 ER - TY - JOUR AU - Cortellini, A. AU - Bersanelli, M. AU - Buti, S. AU - Cannita, K. AU - Santini, D. AU - Perrone, F. PY - 2019 DA - 2019// TI - A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable JO - J Immunother Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0527-y DO - 10.1186/s40425-019-0527-y ID - Cortellini2019 ER - TY - JOUR AU - Fan, C. AU - Prat, A. AU - Parker, J. S. AU - Liu, Y. AU - Carey, L. A. AU - Troester, M. A. PY - 2011 DA - 2011// TI - Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures JO - BMC Med Genomics VL - 4 UR - https://doi.org/10.1186/1755-8794-4-3 DO - 10.1186/1755-8794-4-3 ID - Fan2011 ER - TY - JOUR AU - Jeyakumar, G. AU - Kim, S. AU - Bumma, N. AU - Landry, C. AU - Silski, C. AU - Suisham, S. PY - 2017 DA - 2017// TI - Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy JO - J Immunother Cancer. VL - 5 UR - https://doi.org/10.1186/s40425-017-0287-5 DO - 10.1186/s40425-017-0287-5 ID - Jeyakumar2017 ER - TY - JOUR AU - Choueiri, T. K. AU - Albiges, L. AU - Haanen, J. B. A. G. AU - Larkin, J. M. G. AU - Uemura, M. AU - Pal, S. K. PY - 2019 DA - 2019// TI - Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.101 DO - 10.1200/JCO.2019.37.15_suppl.101 ID - Choueiri2019 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Chen, H. L. AU - Girgis, K. R. AU - Cunningham, H. T. AU - Meny, G. M. AU - Nadaf, S. PY - 1996 DA - 1996// TI - Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm1096-1096 DO - 10.1038/nm1096-1096 ID - Gabrilovich1996 ER - TY - JOUR AU - Bergers, G. AU - Benjamin, L. E. PY - 2003 DA - 2003// TI - Tumorigenesis and the angiogenic switch JO - Nat Rev Cancer VL - 3 UR - https://doi.org/10.1038/nrc1093 DO - 10.1038/nrc1093 ID - Bergers2003 ER - TY - JOUR AU - Hicklin, D. J. AU - Ellis, L. M. PY - 2005 DA - 2005// TI - Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.06.081 DO - 10.1200/JCO.2005.06.081 ID - Hicklin2005 ER - TY - JOUR AU - Kusmartsev, S. AU - Eruslanov, E. AU - Kübler, H. AU - Tseng, T. AU - Sakai, Y. AU - Su, Z. PY - 2008 DA - 2008// TI - Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma JO - J Immunol UR - https://doi.org/10.4049/jimmunol.181.1.346 DO - 10.4049/jimmunol.181.1.346 ID - Kusmartsev2008 ER - TY - JOUR AU - Wallin, J. J. AU - Bendell, J. C. AU - Funke, R. AU - Sznol, M. AU - Korski, K. AU - Jones, S. PY - 2016 DA - 2016// TI - Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12624 DO - 10.1038/ncomms12624 ID - Wallin2016 ER - TY - STD TI - Broad GDAC Firehose. Broad GDAC Firehose, Broad Institute of MIT & Harvard. 2016. https://gdac.broadinstitute.org/. UR - https://gdac.broadinstitute.org/ ID - ref35 ER - TY - JOUR AU - Liu, J. AU - Lichtenberg, T. AU - Hoadley, K. A. AU - Poisson, L. M. AU - Lazar, A. J. AU - Cherniack, A. D. PY - 2018 DA - 2018// TI - An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics JO - Cell VL - 173 ID - Liu2018 ER - TY - STD TI - Genomic Data Commons data portal (GDC). https://portal.gdc.cancer.gov. UR - https://portal.gdc.cancer.gov ID - ref37 ER - TY - JOUR AU - Li, B. AU - Dewey, C. N. PY - 2011 DA - 2011// TI - RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome JO - BMC Bioinformatics VL - 12 UR - https://doi.org/10.1186/1471-2105-12-323 DO - 10.1186/1471-2105-12-323 ID - Li2011 ER - TY - JOUR AU - Benjamini, Y. AU - Drai, D. AU - Elmer, G. AU - Kafkafi, N. AU - Golani, I. PY - 2001 DA - 2001// TI - Controlling the false discovery rate in behavior genetics research JO - Behav Brain Res VL - 125 UR - https://doi.org/10.1016/S0166-4328(01)00297-2 DO - 10.1016/S0166-4328(01)00297-2 ID - Benjamini2001 ER - TY - JOUR AU - Spranger, S. AU - Luke, J. J. AU - Bao, R. AU - Zha, Y. Y. AU - Hernandez, K. M. AU - Li, Y. PY - 2016 DA - 2016// TI - Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma JO - Proc Natl Acad Sci USA VL - 113 UR - https://doi.org/10.1073/pnas.1609376113 DO - 10.1073/pnas.1609376113 ID - Spranger2016 ER - TY - BOOK AU - Cohen, J. PY - 1988 DA - 1988// TI - Statistical Power Analysis for the Behavioral Sciences PB - Routledge Academic CY - New York ID - Cohen1988 ER - TY - JOUR AU - Lakens, D. PY - 2013 DA - 2013// TI - Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs JO - Front Psychol. VL - 4 UR - https://doi.org/10.3389/fpsyg.2013.00863 DO - 10.3389/fpsyg.2013.00863 ID - Lakens2013 ER - TY - JOUR AU - Albiges, L. AU - Hakimi, A. A. AU - Xie, W. AU - McKay, R. R. AU - Simantov, R. AU - Lin, X. PY - 2016 DA - 2016// TI - Body mass index and metastatic renal cell carcinoma: clinical and biological correlations JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.7311 DO - 10.1200/JCO.2016.66.7311 ID - Albiges2016 ER - TY - JOUR AU - Lalani, A. A. AU - Bakouny, Z. AU - Farah, S. PY - 2019 DA - 2019// TI - 976P Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC) JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz249.072 DO - 10.1093/annonc/mdz249.072 ID - Lalani2019 ER - TY - JOUR AU - Iyengar, N. M. AU - Gucalp, A. AU - Dannenberg, A. J. AU - Hudis, C. A. PY - 2016 DA - 2016// TI - Obesity and cancer mechanisms: tumor microenvironment and inflammation JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.4283 DO - 10.1200/JCO.2016.67.4283 ID - Iyengar2016 ER - TY - JOUR AU - Lee, J. Y. AU - Sohn, K. H. AU - Rhee, S. H. AU - Hwang, D. PY - 2001 DA - 2001// TI - Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4 JO - J Biol Chem VL - 276 UR - https://doi.org/10.1074/jbc.M011695200 DO - 10.1074/jbc.M011695200 ID - Lee2001 ER - TY - JOUR AU - Malietzis, G. AU - Aziz, O. AU - Bagnall, N. M. AU - Johns, N. AU - Fearon, K. C. AU - Jenkins, J. T. PY - 2015 DA - 2015// TI - The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review JO - Eur J Surg Oncol VL - 41 UR - https://doi.org/10.1016/j.ejso.2014.10.056 DO - 10.1016/j.ejso.2014.10.056 ID - Malietzis2015 ER - TY - JOUR AU - Young, A. AU - Quach, H. T. AU - Davis, E. J. AU - Moslehi, J. AU - Williams, G. R. AU - Johnson, D. B. PY - 2019 DA - 2019// TI - Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.9516 DO - 10.1200/JCO.2019.37.15_suppl.9516 ID - Young2019 ER - TY - JOUR AU - Naik, G. S. AU - Waikar, S. S. AU - Johnson, A. E. W. AU - Buchbinder, E. I. AU - Haq, R. AU - Hodi, F. S. PY - 2019 DA - 2019// TI - Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition JO - J ImmunoTher Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0512-5 DO - 10.1186/s40425-019-0512-5 ID - Naik2019 ER - TY - JOUR AU - Elias, R. AU - Yan, F. AU - Singla, N. AU - Levonyack, N. AU - Formella, J. AU - Christie, A. PY - 2019 DA - 2019// TI - Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2019.37.7_suppl.645 DO - 10.1200/JCO.2019.37.7_suppl.645 ID - Elias2019 ER - TY - JOUR AU - Morehouse, C. AU - Abdullah, S. E. AU - Gao, C. AU - Dar, M. M. AU - Ranade, K. AU - Higgs, B. W. PY - 2019 DA - 2019// TI - Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs) JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.2563 DO - 10.1200/JCO.2019.37.15_suppl.2563 ID - Morehouse2019 ER - TY - JOUR AU - Freeman-Keller, M. AU - Kim, Y. AU - Cronin, H. AU - Richards, A. AU - Gibney, G. AU - Weber, J. S. PY - 2016 DA - 2016// TI - Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1136 DO - 10.1158/1078-0432.CCR-15-1136 ID - Freeman-Keller2016 ER - TY - JOUR AU - Haratani, K. AU - Hayashi, H. AU - Chiba, Y. AU - Kudo, K. AU - Yonesaka, K. AU - Kato, R. PY - 2018 DA - 2018// TI - Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.2925 DO - 10.1001/jamaoncol.2017.2925 ID - Haratani2018 ER - TY - JOUR AU - Ishihara, H. AU - Takagi, T. AU - Kondo, T. AU - Homma, C. AU - Tachibana, H. AU - Fukuda, H. PY - 2019 DA - 2019// TI - Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab JO - Urol Oncol. UR - https://doi.org/10.1016/j.urolonc.2019.03.003 DO - 10.1016/j.urolonc.2019.03.003 ID - Ishihara2019 ER - TY - JOUR AU - Osorio, J. C. AU - Ni, A. AU - Chaft, J. E. AU - Pollina, R. AU - Kasler, M. K. AU - Stephens, D. PY - 2017 DA - 2017// TI - Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer JO - Ann Oncol VL - 28 ID - Osorio2017 ER - TY - JOUR AU - Ali, O. H. AU - Diem, S. AU - Markert, E. AU - Jochum, W. AU - Kerl, K. AU - French, L. E. PY - 2016 DA - 2016// TI - Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer JO - Oncoimmunology UR - https://doi.org/10.1080/2162402X.2016.1231292 DO - 10.1080/2162402X.2016.1231292 ID - Ali2016 ER - TY - JOUR AU - Ravaud, A. AU - Motzer, R. J. AU - Pandha, H. S. AU - George, D. J. AU - Pantuck, A. J. AU - Patel, A. PY - 2016 DA - 2016// TI - Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy JO - N Engl J Med UR - https://doi.org/10.1056/NEJMoa1611406 DO - 10.1056/NEJMoa1611406 ID - Ravaud2016 ER - TY - JOUR AU - Haas, N. B. AU - Manola, J. AU - Uzzo, R. G. AU - Atkins, M. B. AU - Wilding, G. AU - Pins, M. PY - 2017 DA - 2017// TI - Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial JO - J Clin Oncol UR - https://doi.org/10.1200/jco.2015.33.7_suppl.403 DO - 10.1200/jco.2015.33.7_suppl.403 ID - Haas2017 ER - TY - JOUR AU - Harshman, L. C. AU - Xie, W. AU - Moreira, R. B. AU - Bosse, D. AU - Ruiz Ares, G. J. AU - Sweeney, C. J. PY - 2018 DA - 2018// TI - Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis JO - Cancer VL - 124 UR - https://doi.org/10.1002/cncr.31154 DO - 10.1002/cncr.31154 ID - Harshman2018 ER - TY - JOUR AU - Forde, P. M. AU - Smith, K. N. AU - Chaft, J. E. AU - Hellmann, M. AU - Merghoub, T. AU - Wolchok, J. D. PY - 2019 DA - 2019// TI - NSCLC, early stage neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer JO - Ann Oncol UR - https://doi.org/10.1093/annonc/mdw435.38 DO - 10.1093/annonc/mdw435.38 ID - Forde2019 ER - TY - JOUR AU - Nanda, R. AU - Liu, M. C. AU - Yau, C. AU - Asare, S. AU - Hylton, N. AU - Veer, L. V. t. PY - 2017 DA - 2017// TI - Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.506 DO - 10.1200/JCO.2017.35.15_suppl.506 ID - Nanda2017 ER - TY - JOUR AU - Blank, C. U. AU - Rozeman, E. A. AU - Fanchi, L. F. AU - Sikorska, K. AU - Wiel, B. v. d. AU - Kvistborg, P. PY - 2018 DA - 2018// TI - Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0198-0 DO - 10.1038/s41591-018-0198-0 ID - Blank2018 ER - TY - JOUR AU - Amaria, R. N. AU - Reddy, S. M. AU - Tawbi, H. A. AU - Davies, M. A. AU - Ross, M. I. AU - Glitza, I. C. PY - 2018 DA - 2018// TI - Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0197-1 DO - 10.1038/s41591-018-0197-1 ID - Amaria2018 ER - TY - JOUR AU - Harshman, L. C. AU - Puligandla, M. AU - Haas, N. B. AU - Allaf, M. AU - Drake, C. G. AU - McDermott, D. F. PY - 2019 DA - 2019// TI - PROSPER: a phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143) JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS4597 DO - 10.1200/JCO.2019.37.15_suppl.TPS4597 ID - Harshman2019 ER - TY - JOUR AU - Giraldo, N. A. AU - Becht, E. AU - Pagès, F. AU - Skliris, G. AU - Verkarre, V. AU - Vano, Y. PY - 2015 DA - 2015// TI - Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer JO - Clin Cancer Res UR - https://doi.org/10.1158/1078-0432.CCR-14-2926 DO - 10.1158/1078-0432.CCR-14-2926 ID - Giraldo2015 ER - TY - JOUR AU - Rosenberg, S. A. AU - Yang, J. C. AU - White, D. E. AU - Steinberg, S. M. PY - 1998 DA - 1998// TI - Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response JO - Ann Surg VL - 228 UR - https://doi.org/10.1097/00000658-199809000-00004 DO - 10.1097/00000658-199809000-00004 ID - Rosenberg1998 ER - TY - JOUR AU - Ghatalia, P. AU - Gordetsky, J. AU - Kuo, F. AU - Dulaimi, E. AU - Cai, K. Q. AU - Devarajan, K. PY - 2019 DA - 2019// TI - Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma JO - J ImmunoTher Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0621-1 DO - 10.1186/s40425-019-0621-1 ID - Ghatalia2019 ER - TY - JOUR AU - Gao, J. AU - Karam, J. A. AU - Tannir, N. M. AU - Slack, R. AU - Ahrar, K. AU - Rao, P. PY - 2018 DA - 2018// TI - A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx) JO - J Clin Oncol UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.4520 DO - 10.1200/JCO.2018.36.15_suppl.4520 ID - Gao2018 ER -